Actelion Ltd is set to acquire Ceptaris Therapeutics Inc of the US pending Food and Drug Administration approval of that company’s product for mycosis fungoides, a rare form of non-Hodgkin’s lymphoma. The upfront payment is $25 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
